Role of DNA Methylation in the Development of Diffuse-Type Gastric Cancer

Eiichiro Yamamoto\textsuperscript{a, b}, Hiromu Suzuki\textsuperscript{a, b}, Hiroyuki Takamaru\textsuperscript{a}
Hiroyuki Yamamoto\textsuperscript{a}, Minoru Toyota\textsuperscript{b}, Yasuhisa Shinomura\textsuperscript{a}

\textsuperscript{a}First Department of Internal Medicine and \textsuperscript{b}Department of Biochemistry, Sapporo Medical University, Sapporo, Japan

Abstract
Cancer cells exhibit two opposing methylation abnormalities: genome-wide hypomethylation and gene promoter hypermethylation. Downregulation of E-cadherin (CDH1) plays a key role in the development of diffuse-type gastric cancer, and DNA methylation is a major cause of the gene’s silencing. Hereditary diffuse gastric cancer is caused by germline mutation of CDH1 gene, and DNA methylation frequently serves as the second hit completely inactivating the gene. In sporadic diffuse-type gastric cancer, methylation of CDH1 is more prevalent than mutation of the gene. Epstein-Barr virus (EBV)-associated gastric carcinoma (EBV-associated GC) is characterized by concurrent methylation of multiple genes, and diffuse-type gastric cancer is frequently seen among EBV-associated GCs. Patients with pangastritis or enlarged-fold gastritis, which are both caused by \textit{Helicobacter pylori} infection, reportedly have an increased risk for diffuse-type gastric cancer. Notably, the gastric mucosa of enlarged-fold gastritis patients exhibits CDH1 hypermethylation and genome-wide hypomethylation. These data suggest that aberrant DNA methylation is an essential promoter of carcinogenesis in individuals at high risk for diffuse-type gastric cancer.

Key Words
Diffuse-type gastric cancer · \textit{Helicobacter pylori} · Epstein-Barr virus · DNA methylation

Introduction
Gastric cancer is one of the most commonly occurring malignant neoplasms, worldwide, and remains a leading cause of cancer death in Asia and some European countries \cite{1}. It is clear that the major etiologic risk factor for gastric cancer is \textit{Helicobacter pylori} infection \cite{2}; however, only a small proportion of individuals infected with \textit{H. pylori} develop gastric cancer, and it is difficult for physicians to conduct proper early detection and prevention of the disease. Consequently, the development of appropriate biomarkers that reflect an individual’s cancer risk is essential to reduce morality from gastric cancer.

Gastric cancers are divided into two distinct histological groups, intestinal and diffuse \cite{3}. Differences in the clinicopathological characteristics between these two types indicate that they develop via distinct molecular pathways. Intestinal-type cancers are histologically differentiated and are thought to be derived from gastric...
mucosa cells. It is believed that *H. pylori* infection plays a pivotal role in the development of intestinal-type gastric cancer, which arises from chronic gastritis, atrophy and intestinal metaplasia. Indeed, it is well known that patients with high-grade atrophic gastritis and intestinal metaplasia are at high risk of developing gastric cancer. On the other hand, the sequence of events via which histologically undifferentiated diffuse-type gastric cancers develop is poorly understood, though it is thought that a subset of diffuse-type gastric cancers develop independently of atrophic gastritis or intestinal metaplasia. In contrast to hereditary diffuse gastric cancer (HDGC), *H. pylori* and/or Epstein-Barr virus (EBV) infections reportedly play essential roles in the development of sporadic diffuse-type gastric cancers. In particular, patients with *H. pylori* infection, are reportedly at increased risk of developing diffuse-type gastric cancer [2, 4, 5].

Cancer is thought to arise through the accumulation of multiple genetic alterations, leading to activation of oncogenes and loss of function of tumor-suppressor genes. With respect to the latter, mutation of p53 gene is seen in approximately 40% of intestinal-type gastric cancers, but it is rare in diffuse-type gastric cancers [6, 7]. CDH1, which encodes E-cadherin, is frequently mutated in sporadic diffuse-type gastric cancers [8], and germline mutations of CDH1 are detected in a subset of HDGC patients [9]. In addition, activation of Wnt signaling through mutation of APC is a common feature of colorectal cancer, and APC mutation is also frequently seen in gastric adenoma. By contrast, APC mutation is not often seen in either intestinal- and diffuse-type gastric cancers [6, 7, 10]. With respect to oncogenes, activating mutation of CTNNB1, which encodes β-catenin, is seen in approximately 20% of intestinal-type gastric cancers [11], while the frequency of KRAS mutation is low in both histological types [10]. Taken together, these data suggest that, as compared to other cancer types (e.g. colorectal cancers), genetic mutations are relatively infrequent in gastric cancer [12].

A growing body of evidence now suggests that, in addition to genetic alterations, epigenetic changes, including DNA methylation and histone modification, also play important roles in the development and progression of human malignancies [13–16]. Epigenetics are inherited factors that influence gene activity but do not alter primary DNA sequences; among them, DNA methylation is a key event that silences gene expression. It has been hypothesized that DNA methylation initially evolved as a defense mechanism against viruses and other DNA pathogens. Under normal physiological conditions, DNA methylation plays a role in genome imprinting, X-chromosome inactivation and inactivation of repetitive sequences. In cancer, however, two contradicting epigenetic events coexist, namely global hypomethylation, which is mainly observed in repetitive sequences within the genome, and regional hypermethylation, which is frequently associated with CpG islands in gene promoters. Global hypomethylation is thought to be associated with proto-oncogene activation and chromosomal instability, whereas regional hypermethylation leads to inactivation of tumor-suppressor genes.

A number of studies provide evidence that both genetic and epigenetic alterations play critical roles in gastric tumorigenesis. For example, approximately 20% of intestinal-type gastric cancers show microsatellite instability that is closely associated with hypermethylation of MLH1 gene [17, 18]. A number of tumor-suppressor and tumor-related genes, including APC, CDH1 (E-cadherin), CHFR, DAPK, GSTP1, p16 and RUNX3, are known to be silenced by hypermethylation in gastric cancer [15, 16, 19]. Moreover, such methylation is frequently observed at premalignant stages of gastric cancer (e.g. with chronic gastritis and intestinal metaplasia), suggesting that aberrant methylation occurs early during the multistep process of gastric carcinogenesis [20–23]. Accumulation of aberrant methylation is thought to promote carcinogenesis through activation of common cancer pathways. For instance, although genetic mutation of APC or CTNNB1 is relatively infrequent in gastric cancer, a number of negative regulators of Wnt signaling, including SFRP1, SFRP2, DKK2, DKK3 and WIF1, are frequently methylated in gastric cancer [24–26]. In addition, methylation of RASSF family genes is thought to serve as an alternative to KRAS mutation in the signaling pathway leading to activation the Ras [27].

Mounting evidence suggests that diffuse-type gastric cancer is strongly associated with aberrant DNA methylation. A subset of cancers that exhibit concurrent hypermethylation of multiple genes is thought to represent a CpG island methylator phenotype (CIMP) [28]. In colorectal cancer, CIMP is strongly associated with MLH1 methylation and microsatellite instability [28]. In gastric cancer, however, CIMP is frequently observed in diffuse-type cancers in which MLH1 methylation and microsatellite instability are less frequent [29]. In this review, we will highlight the contribution made by DNA methylation to the development of diffuse-type gastric cancer, and its clinical application as a potential biomarker.
Hereditary Diffuse Gastric Cancer

According to the International Gastric Cancer Linkage Consortium, HDGC is clinically characterized by either (1) two or more documented cases of diffuse gastric cancer in first- or second-degree relatives with at least one diagnosed before age 50 years, or (2) three or more cases of documented diffuse gastric cancer in first- or second-degree relatives, independent of the age of onset [30]. HDGC is an autosomal-dominant inherent cancer syndrome, and approximately 30% of individuals with a clinical diagnosis of HDGC harbor germline mutation of CDH1 [31, 32]. Among individuals with CDH1 germline mutations, the cumulative risk of advanced gastric cancer by age 80 years is 69% in men and 83% in women [33].

CDH1 is located on chromosome 16q22.1 and encodes E-cadherin, which is a transmembrane homodimeric protein that is central to calcium-dependent adhesion of epithelial cells. The mature protein is comprised of three major domains: a large extracellular domain and smaller transmembrane and cytoplasmic domains. The N-terminal ends of the large extracellular domains of the dimers interact with similar E-cadherin dimers on opposing cell surfaces, while the C-terminal ends of the cytoplasmic domains associate with the actin cytoskeleton via a complex that includes α-catenin, β-catenin and γ-catenin. And by competing with APC for binding to β-catenin, E-cadherin also modulates activity in the intracellular β-catenin signaling pathway [34]. Loss of E-cadherin is believed to lead to loss of cell adhesion, which would promote invasion and metastasis. Among all the reported CDH1 germline mutations, approximately 80% are predicted to generate truncated E-cadherin transcripts (nonsense, splice-site and frameshift mutations), while the remaining 20% are missense mutations [31, 35].

In addition to genetic mutation or allelic loss, epigenetic gene silencing associated with DNA methylation is now recognized as an alternative mechanism by which tumor-suppressor genes are inactivated. Within the mammalian genome, DNA methylation occurs only at cytosine bases located 5' to a guanosine in a CpG dinucleotide (fig. 1). This dinucleotide is actually underrepresented in much of the genome, but short regions (<1500 bp in length) known as CpG islands are rich in CpG dinucleotides [36]. The majority of CpG islands are found in the 5' end regions of approximately half of the genes in the human genome, and are generally unmethylated in normal cells. By contrast, a number of tumor-suppressor and tumor-associated genes are hypermethylated and transcriptionally inactivated in cancer cells (fig. 2). CDH1 promoter methylation and intragenic deletions in the wild-type allele are frequently observed in HDGC and
are thought to serve as a second hit that completely inactivates the gene [37, 38], although the specific mechanisms by which DNA methylation is altered in cancer remain unclear. Recently, the use of endogastric capsules has enabled successful detection of CDH1 methylation in DNA from the gastric juice of diffuse-type gastric cancer patients [39]. Because methylation is one of the major mechanisms involved in the second hit in CDH1 germ-line mutation carriers, assessing the methylation of CDH1 in gastric juice could be a non-invasive way of detecting individuals carrying mutations that put them at greater risk of developing HDGC.

**Epstein-Barr Virus-Associated Gastric Carcinoma**

EBV is a ubiquitous human herpes virus that was first identified in Burkitt’s lymphoma cells. EBV is transmitted from host to host mainly via saliva, and has been established as a persistent infection of B-cells in over 90% of the world’s adult population [40]. EBV does not usually replicate in B-cells, but instead establishes a latent infection characterized by limited expression of a subset of latent virus genes. Although the vast majority of EBV infections remain asymptomatic throughout one’s entire life, a small portion of infected individuals develop tumors, and EBV has been implicated in the oncogenesis of lymphoproliferative diseases such as Burkitt’s lymphoma and Hodgkin lymphoma. EBV has also been detected in certain epithelial tumors, including carcinomas of the nasopharynx and stomach.

EBV-associated gastric carcinoma (EBV-associated GC) is defined by the presence of EBV within tumor cells [41–43]. EBV, or its small non-coding RNA (EBER1 and EBER2), has been identified in nearly all neoplastic cells in EBV-associated GC tissue samples. Burke et al. [44] first reported detecting the EBV genome in lymphoepithelioma-like carcinoma, which accounts for approximately 1% of gastric cancers. Lymphoepithelioma-like carcinomas are almost always EBV-positive, and are characterized as a poorly differentiated carcinoma with dense infiltration of lymphocytes. EBV is also detected in about 5–10% of ordinary types of gastric cancer. EBV-associated GCs are observed among all types of gastric adenocarcinoma, but they are slightly more common in moderately differentiated tubular types and poorly differentiated solid types. EBV-associated GCs are also more likely in males than females, and are less likely to be found in the gastric antrum than in the cardia or body.

Evidence suggests that epigenetic abnormalities play pivotal roles in the development of EBV-associated GC. Although p53 mutations are found in about 30–40% of gastric cancers, p53 is mutated in less than 10% of EBV-associated GCs [42, 43]. In contrast, hypermethylation of tumor-suppressor genes such as CDH1, p14, p15 and p16 is frequently observed in EBV-associated GC [43, 45]. In particular, simultaneous hypermethylation of the promoters of multiple genes (i.e. CIMP) is a characteristic abnormality in EBV-associated GC [29, 46–48]. CIMP was originally defined in the context of gastric cancer using methylation of five CIMP marker loci (MINT1, 2, 12, 25 and 31) identified by Toyota et al. [49]. Tumors showing methylation of 4 or 5 of the markers were defined as CIMP-high (CIMP-H), while those with 1–3 markers were CIMP-low (CIMP-L), and those with no methylation were CIMP-negative (CIMP-N) [29]. Tumors showing methylation of 4 or 5 of the markers were defined as CIMP-high (CIMP-H), while those with 1–3 markers were CIMP-low (CIMP-L), and those with no methylation were CIMP-negative (CIMP-N) [29]. To further characterize CIMP in gastric cancer, we assessed the methylation status of 12 other genes (BNIP3, CHFR, CSPG2, p16, HLF, HRK, PAX5β, SLC5A8, p57, MLH1, SOCS-3, TIG1) and compared it with the tumors’ CIMP status [29]. We found that 24% of gastric cancers are CIMP-H, as are all EBV-positive cancers, which accounts for approximately half of the CIMP-H tumors. As compared to the CIMP-L/CIMP-N group, CIMP-H tumors show frequent methylation of the aforementioned 12 genes, and are positively associated
Role of DNA Methylation in Diffuse-Type Gastric Cancer

with upper stomach localization and diffuse-type of histology. And when Chang et al. [47] used five different genes (LOX, HRASLS, FLNc, HAND1 and TM) as CIMP markers and defined CIMP using the same criteria as Toyota et al. [49] – i.e., tumors with >4 markers were defined as CIMP-H, those with 1–3 marker were CIMP-intermediate (CIMP-I), and those without methylation were CIMP-N – they too found that 24% of gastric cancers are CIMP-H, as are nearly all cases of EBV-associated GC.

Interestingly, EBV-negative CIMP-H gastric cancers are strongly associated with MLH1 methylation and microsatellite instability, whereas EBV-positive CIMP-H gastric cancers are strongly associated with diffuse-type of histology and rarely show MLH1 methylation [29, 46–48]. It thus appears that EBV-positive and -negative cancers represent distinct subclasses among CIMP-H gastric cancers. Given that DNA methylation is utilized as a host defense mechanism to suppress the expression of viral genes, it is plausible that EBV may activate a methylation pathway that affects multiple genes during gastric carcinogenesis, although the molecular mechanism underlying EBV-associated aberrant methylation is currently unknown.

Synchronous multicentric cancers are frequently reported in EBV-associated GC patients, suggesting that, with EBV infection, the gastric mucosa is at high risk of carcinogenesis. A marked degree of atrophy and a moderate to marked degree of lymphocytic infiltration were observed in the mucosa surrounding EBV-associated GC, but not EBV-negative GC. It is plausible that *H. pylori* infection is associated with the atrophy and inflammation in the gastric mucosa surrounding EBV-associated GC, although it is still controversial whether the rate of *H. pylori* infection is higher among EBV-positive individuals than among those that are not infected. In situ hybridization analysis revealed that EBERs are rarely expressed in non-neoplastic epithelia adjacent to gastric cancers, but are present in a small portion of infiltrating lymphocytes [50, 51]. In addition, p14, p16 and p73 are commonly methylated in EBV-associated GC, whereas methylation was less frequently detected in surrounding non-neoplastic mucosa [52]. To date, there have been no studies examining CDH1 methylation in the gastric mucosa surrounding EBV-associated GC. Further analysis of aberrant DNA methylation in both EBV-associated GC and the adjacent gastric mucosa may lead to identification of new molecular markers for risk prediction and early diagnosis.

![Fig. 3. Association between fold width, histological type and location of gastric cancers. The results are derived from Nishibayashi et al. [5].](image-url)
cancer [2]. It is also well known that nodularity in the gastric antrum and enlarged fold in the gastric body initiated by H. pylori infection are indicators of a high risk of diffuse-type gastric cancer [2, 4, 5]. Moreover, the prevalence of diffuse-type gastric cancer in the gastric body region increases with increasing fold width (fig. 3). Taken together, these findings suggest that enlarged-fold gastritis puts one at high risk of developing diffuse-type gastric cancer. Further study of aberrant DNA methylation in pangastritis, nodular gastritis, enlarged-fold gastritis and in the non-cancerous gastric mucosa of diffuse-type gastric cancer patients should help to clarify the pathogenesis of diffuse-type gastric cancer and lead to identification of molecular markers to predict cancer risk.

**Aberrant DNA Methylation in H. pylori-Related Enlarged-Fold Gastritis**

Enlarged gastric folds are associated with a variety of diseases, including hypertrophic gastritis, Ménétrier disease, Zollinger-Ellison syndrome, primary gastrin cell hyperplasia, gastric cancer and lymphoma. The accumulated evidence suggests H. pylori-induced gastritis is also a possible cause of enlarged gastric folds [64–66]. H. pylori reportedly causes the enlarged-fold gastritis (fold width >5 mm) that accompanies foveolar hyperplasia, massive infiltration of inflammatory cells, and increased production of interleukin-1β (IL-1β) and hepatocyte growth factor (HGF) in the corpus mucosa. The prevalence of enlarged-fold gastritis is higher in middle-aged (40- to 59-year-old) males than in men in other age groups or in females. It has also been reported that the prevalence of diffuse-type gastric cancer in the gastric body region increases with increasing fold width, suggesting enlarged-fold gastritis is a major risk factor for diffuse-type gastric cancer. In addition, the mutagenicity of gastric juice and mucosal levels of 8-hydroxydeoxyguanidine, an indicator of reactive oxygen species-induced DNA damage, in the body regions of the stomach in patients with enlarged-fold gastritis were significantly higher than in either H. pylori-negative controls or H. pylori-positive patients without enlarged folds [5]. Increased production of IL-1β and HGF, increased serum gastrin levels, and decreased acid secretion are all associated with enlarged-fold gastritis and are thought to promote gastric tumorigenesis [64, 67].

Aberrant DNA methylation is frequently observed in enlarged-fold gastritis. CDH1 methylation is detected in almost all cases of H. pylori-induced enlarged-fold gastritis, and quantitative methylation analysis revealed that levels of CDH1 methylation are much higher in enlarged-fold gastritis than in H. pylori-positive gastritis without enlarged folds [68, 69]. Detailed methylation analysis using bisulfite sequencing revealed that CDH1 is densely methylated in enlarged-fold gastritis [69], and that expression of E-cadherin is downregulated in the gastric mucosa of enlarged-fold gastritis [68]. Furthermore, a significant reduction in the level of CDH1 methylation is seen after H. pylori eradication [68]. These results strongly suggest that hypermethylation of CDH1 is a major contributor to the development of diffuse-type gastric cancer. It has also been reported that treatment of the MKN-1 gastric cancer cell line with transforming growth factor-α, epidermal growth factor (EGF) or reactive oxygen species induces CDH1 methylation, and that EGF treatment upregulated DNA methyltransferase activity [68]. Thus, inflammatory cytokines, growth factors and reactive oxygen species induced by H. pylori infection are likely involved in CDH1 methylation. This suggests CDH1 methylation could be a molecular marker predicting the development of diffuse-type gastric cancer risk.

More than 40% of the human genome is composed of repetitive sequences, including long interspersed nuclear element (LINE) and short interspersed nuclear element, and the methylation level of the former has been used as a surrogate for global methylation levels [70]. LINE-1 hypomethylation is known to occur during the development of various human malignancies, and it is reportedly associated with tumor malignancy and a poor prognosis [71–75]. One recent study revealed that levels of LINE-1 methylation are significantly reduced in the mucosa from patients with enlarged-fold gastritis [69]. The role of hypomethylation in tumorigenesis is not fully understood, but it is thought to induce activation of proto-oncogenes, endogenous retroviruses or transposable elements, as well as chromosomal instability. A link between LINE-1 hypomethylation and gene promoter hypermethylation (CDH1, CDH13 and PGP9.5) was also found in enlarged-fold gastritis [69]. CDH13 encodes H-cadherin, which is involved in suppressing cell growth, invasion and metastasis, is frequently methylated in gastric cancer [76]. In addition, PGP9.5 was identified in a screening for epigenetically silenced genes in diffuse-type gastric cancer, and it has been shown to serve as a tumor suppressor in gastric cancer [77]. Thus, gene hypermethylation and global hypomethylation both appear to be forces driving the development of diffuse-type cancer in enlarged-fold gastritis (fig. 4). Further analysis of aberrant DNA meth-
Role of DNA Methylation in Diffuse-Type Gastric Cancer

Digestion 2011;83:241–249

Fig. 4. Hypothesis for the progression of gastric cancer in \textit{H. pylori}-induced enlarged-fold gastritis.

In patients with enlarged-fold gastritis, inflammatory infiltrates, cytokine release, foveolar thickness and fold width are all significantly reduced after eradication of \textit{H. pylori} [66]. Eradication of \textit{H. pylori} also restores acid secretion and decreases serum gastrin concentrations [64]. Reduction of CDH1 methylation after \textit{H. pylori} eradication in chronic gastritis has also been reported [78–80]. It is thus possible that eradication of \textit{H. pylori} reduces the risk of diffuse-type gastric cancer; however, eradication does not completely restore normal DNA methylation, and individuals with sustained alteration of DNA methylation are thought to be at higher risk, even after \textit{H. pylori} eradication. Evaluation of DNA methylation after eradication also may serve as a useful diagnostic tool for predicting cancer development, although further study is needed to clarify the relationship between residual methylation and cancer risk after eradication.

Prospects

From the available evidence, it is clear that both genetic and epigenetic alterations play an important role in the development of diffuse-type gastric cancer. \textit{H. pylori} infection induces aberrant DNA methylation of multiple genes, including CDH1, in gastric mucosa and enlarged-fold gastritis, which puts the patient at high risk for diffuse-type gastric cancer. In addition, global hypomethylation is also commonly observed in enlarged-fold gastritis. Further study of DNA methylation in high-risk individuals should not only clarify the mechanism underlying gastric carcinogenesis, but may also lead to the development of new molecular markers for risk prediction and early detection of gastric cancer.

Acknowledgement

We thank Dr. W.F. Goldman for editing the manuscript.

References

Diffuse-Type Gastric Cancer

Mechanisms inactivated by DNA methylation in diffuse-type gastric cancer


